Evidence map›Paper›PMID 30884214›Full record

ArticleCPT: pharmacometrics & systems pharmacology2019

The Risk of Treating Populations Instead of Patients.

Amelia N Deitchman

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Amelia N DeitchmanSchool of Pharmacy, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-4722-463X

Funding

CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICST32GM007546 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Radojka Savic · 1985 to 2026
$8.9M
Target based discovery of next generation pyrazinamideR01AI106398 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DICK, THOMAS · 2013 to 2022
$7.1M
De facto monotherapy during multidrug TB treatment and emergence of resistanceR01AI111967 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, DARTOIS, VERONIQUE · 2014 to 2018
$4.2M
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug ResistanceR01AI111992 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DOOLEY, KELLY E., NUERMBERGER, ERIC L · 2014 to 2018
$3.5M
NIAID NIH HHS R01 AI106398NIAID NIH HHS R01 AI111967NIAID NIH HHS R01 AI111992NIGMS NIH HHS T32 GM007546
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Dosage CalculationsHumansModels, TheoreticalPalivizumabPrecision MedicineRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsPalivizumab

Identifiers

PMID30884214
PMCPMC6539720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.